Pete Spain - Kura Oncology Executive Communications
| KURA Stock | USD 10.06 5.85 36.77% |
Executive
Pete Spain is Executive Communications of Kura Oncology
| Address | 12730 High Bluff Drive, San Diego, CA, United States, 92130 |
| Phone | 858 500 8800 |
| Web | https://kuraoncology.com |
Kura Oncology Management Efficiency
The company has return on total asset (ROA) of (0.2854) % which means that it has lost $0.2854 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4628) %, meaning that it created substantial loss on money invested by shareholders. Kura Oncology's management efficiency ratios could be used to measure how well Kura Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.36. The current year's Return On Capital Employed is expected to grow to -0.38. At present, Kura Oncology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 454.1 M, whereas Return On Tangible Assets are forecasted to decline to (0.36).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matthew Gosling | Protagonist Therapeutics | 53 | |
| Robert Shoemaker | Erasca Inc | 43 | |
| Emily Hill | Replimune Group | 44 | |
| Evan JD | Cogent Biosciences | 44 | |
| Pamela Esposito | Replimune Group | 50 | |
| Richard Shames | Protagonist Therapeutics | 64 | |
| Carsten Boess | Kiniksa Pharmaceuticals | 58 | |
| John Berman | Larimar Therapeutics | N/A | |
| Christi Waarich | Cogent Biosciences | N/A | |
| Seth Harmon | Viridian Therapeutics | 44 | |
| Andrea JD | Zentalis Pharmaceuticals Llc | 43 | |
| DO Sr | Larimar Therapeutics | 63 | |
| Gopi MBA | Larimar Therapeutics | 53 | |
| John Paolini | Kiniksa Pharmaceuticals | 59 | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Melissa Manno | Viridian Therapeutics | N/A | |
| Martina Struck | Kiniksa Pharmaceuticals | N/A | |
| Sr DO | Larimar Therapeutics | 63 | |
| Dana PharmD | Cogent Biosciences | N/A | |
| Michael PharmD | Kalvista Pharmaceuticals | 44 | |
| Mohammad Masjedizadeh | Protagonist Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.29 |
Kura Oncology Leadership Team
Elected by the shareholders, the Kura Oncology's board of directors comprises two types of representatives: Kura Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kura. The board's role is to monitor Kura Oncology's management team and ensure that shareholders' interests are well served. Kura Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kura Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathleen Ford, Chief Officer | ||
| Mollie MD, Executive Development | ||
| Francis Burrows, Senior Research | ||
| Roger Bakale, Clinical CMC | ||
| JD Esq, Chief Secretary | ||
| Marc MD, Advisor | ||
| Stephen MD, Chief Officer | ||
| Thomas Doyle, Principal Accounting | ||
| Esq JD, Chief Sec | ||
| MS MBA, Chief Officer | ||
| Troy JD, CEO, Chairman | ||
| Kirsten Flowers, Chief Officer | ||
| Pete Spain, Executive Communications | ||
| Maureen MBA, VP Management |
Kura Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kura Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 343.64 M | ||||
| Shares Outstanding | 77.76 M | ||||
| Shares Owned By Insiders | 1.05 % | ||||
| Shares Owned By Institutions | 98.95 % | ||||
| Number Of Shares Shorted | 10.8 M | ||||
| Price To Earning | (9.03) X | ||||
| Price To Book | 1.85 X | ||||
| EBITDA | (164.96 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.35) | Return On Assets (0.29) | Return On Equity (0.46) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.